Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling

Autor: Mengyang Fan, Wenchao Lu, Jianwei Che, Nicholas P Kwiatkowski, Yang Gao, Hyuk-Soo Seo, Scott B Ficarro, Prafulla C Gokhale, Yao Liu, Ezekiel A Geffken, Jimit Lakhani, Kijun Song, Miljan Kuljanin, Wenzhi Ji, Jie Jiang, Zhixiang He, Jason Tse, Andrew S Boghossian, Matthew G Rees, Melissa M Ronan, Jennifer A Roth, Joseph D Mancias, Jarrod A Marto, Sirano Dhe-Paganon, Tinghu Zhang, Nathanael S Gray

Publikováno v: eLife, Vol 11 (2022)

The transcription factor TEAD, together with its coactivator YAP/TAZ, is a key transcriptional modulator of the Hippo pathway. Activation of TEAD transcription by YAP has been implicated in a number of malignancies, and this complex represents a prom

Externí odkaz: https://doaj.org/article/885c81e0f1964e4e986cf2271d9a8b62

Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias

Autor: Ricardo de Matos Simoes, Ryosuke Shirasaki, Sondra L. Downey-Kopyscinski, Geoffrey M. Matthews, Benjamin G. Barwick, Vikas A. Gupta, Daphné Dupéré-Richer, Shizuka Yamano, Yiguo Hu, Michal Sheffer, Eugen Dhimolea, Olga Dashevsky, Sara Gandolfi, Kazuya Ishiguro, Robin M. Meyers, Jordan G. Bryan, Neekesh V. Dharia, Paul J. Hengeveld, Johanna B. Brüggenthies, Huihui Tang, Andrew J. Aguirre, Quinlan L. Sievers, Benjamin L. Ebert, Brian J. Glassner, Christopher J. Ott, James E. Bradner, Nicholas P. Kwiatkowski, Daniel Auclair, Joan Levy, Jonathan J. Keats, Richard W. J. Groen, Nathanael S. Gray, Aedin C. Culhane, James M. McFarland, Joshua M. Dempster, Jonathan D. Licht, Lawrence H. Boise, William C. Hahn, Francisca Vazquez, Aviad Tsherniak, Constantine S. Mitsiades

Publikováno v: de Matos Simoes, R, Shirasaki, R, Downey-Kopyscinski, S L, Matthews, G M, Barwick, B G, Gupta, V A, Dupéré-Richer, D, Yamano, S, Hu, Y, Sheffer, M, Dhimolea, E, Dashevsky, O, Gandolfi, S, Ishiguro, K, Meyers, R M, Bryan, J G, Dharia, N V, Hengeveld, P J, Brüggenthies, J B, Tang, H, Aguirre, A J, Sievers, Q L, Ebert, B L, Glassner, B J, Ott, C J, Bradner, J E, Kwiatkowski, N P, Auclair, D, Levy, J, Keats, J J, Groen, R W J, Gray, N S, Culhane, A C, McFarland, J M, Dempster, J M, Licht, J D, Boise, L H, Hahn, W C, Vazquez, F, Tsherniak, A & Mitsiades, C S 2023, ' Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias ', Nature Cancer, vol. 4, no. 5, pp. 754-773 . https://doi.org/10.1038/s43018-023-00550-x
Nature Cancer, 4(5), 754-773. Nature Research

Clinical progress in multiple myeloma (MM), an incurable plasma cell (PC) neoplasia, has been driven by therapies that have limited applications beyond MM/PC neoplasias and do not target specific oncogenic mutations in MM. Instead, these agents targe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c38520e5128234e34753590416d0e64
https://doi.org/10.1038/s43018-023-00550-x

Human Polo-like Kinase Inhibitors as Antiplasmodials

Autor: Monica J. Bohmer, Jinhua Wang, Eva S. Istvan, Madeline R. Luth, Jennifer E. Collins, Edward L. Huttlin, Lushun Wang, Nimisha Mittal, Mingfeng Hao, Nicholas P. Kwiatkowski, Steven P. Gygi, Ratna Chakrabarti, Xianming Deng, Daniel E. Goldberg, Elizabeth A. Winzeler, Nathanael S. Gray, Debopam Chakrabarti

Publikováno v: ACS Infectious Diseases. 9:1004-1021

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6d1095be44db8cc485df1077fb5d3391
https://doi.org/10.1021/acsinfecdis.3c00025

Data from A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non–Small Cell Lung Cancer

Autor: Pasi A. Jänne, Nathanael S. Gray, Michael J. Eck, Michael D. Cameron, Prafulla C. Gokhale, Man Xu, Stephen Wang, Michael J. Poitras, Pinar Ö. Eser, Nicholas P. Kwiatkowski, John M. Hatcher, Mika Lin, Alyssa Verano, Heidi M. Haikala, Yoonji Eum, Tyler S. Beyett, Jaebong Jang, Jieun Son

In-frame insertions in exon 20 of HER2 are the most common HER2 mutations in patients with non–small cell lung cancer (NSCLC), a disease in which approved EGFR/HER2 tyrosine kinase inhibitors (TKI) display poor efficiency and undesirable side effec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::97a8ef884fce9cee6f7c5310978d793e
https://doi.org/10.1158/0008-5472.c.6513855.v1

Supplementary Table 1 from Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR

Autor: Nathanael S. Gray, David M. Sabatini, Kwok-Kin Wong, Pasi A. Janne, Stephen J. Elledge, Danny M. Chou, Kathryn D. Held, Hidemasa Kawamura, Abigail Altabef, Tanya Tupper, Yuchuan Wang, Matthew P. Patricelli, Seong A. Kang, Carson C. Thoreen, Mario Niepel, Dalia Ercan, Peng Gao, Kenneth D. Westover, Jinhua Wang, Nicholas P. Kwiatkowski, Yan Liu, Wooyoung Hur, Xin Zhang, Sivapriya Kirubakaran, Chunxiao Xu, Qingsong Liu

PDF file - 401K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cfd6389bcfe5cc37d8e136047ce9803
https://doi.org/10.1158/0008-5472.22398723.v1